Pure Global AI
NCT05974007Recruiting

Neoadjuvant Treatment Real-world Clinical Outcomes in NSCLC

Neoadjuvant Treatment Real-world Clinical Outcomes in NSCLC: A Retrospective Multi-center Study (NeoR-World)
Cancer Institute and Hospital, Chinese Academy of Medical SciencesClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Non-Small Cell Lung Cancer
Drug/Device/Intervention
Neoadjuvant immunochemotherapy
Study type
Observational
Intervention type
drug
Sponsor & location
Primary sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Location
Beijing, China
Timeline & enrollment
Phase
N/A
Start date
Jan 01, 2022
End date
Jun 01, 2026
Enrollment
1500 participants
Primary outcome

Disease-free survival(DFS),Pathological Complete Response (pCR)

Summary

Despite the clinical success of immune checkpoint blockade (ICB), in neoadjuvant setting,
 there is still a lack of valid data for operable NSCLC in the real world. This study aim to
 compare the clinical outcomes (pathologic response rate versus survival) of neoadjuvant
 immunochemotherapy with neoadjuvant chemotherapy in the real world, to explore the impact of
 clinicopathological factors on clinical outcomes in neoadjuvant immunochemotherapy setting,
 and to identify potential neoadjuvant immunochemotherapy beneficiaries.

ICD-10 classifications
Secondary malignant neoplasm of lungMalignant neoplasm: Lower lobe, bronchus or lungMalignant neoplasm: Middle lobe, bronchus or lungMalignant neoplasm: Bronchus or lung, unspecifiedMalignant neoplasm of bronchus and lung
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05974007
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05974007 through Pure Global AI's free database. This phase not specified trial is sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences and is currently Recruiting. The study focuses on Non-Small Cell Lung Cancer. Target enrollment is 1500 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.